Background {#Sec1}
==========

Sarcoidosis is a systemic granulomatous disease of unknown cause. A genetic predisposition is suggested by familial histories and the risk for the disease multiplied by 80 in monozygotic twins of index cases \[[@CR1], [@CR2]\]. Genome-wide association studies and candidate gene-driven investigations identified several genetic risk foci for sarcoidosis, including butyrophilin-like 2 gene \[[@CR3]--[@CR5]\], Annexin 11 \[[@CR6]\], a locus on chromosome 11q13.1 \[[@CR7]\], several loci in the HLA region \[[@CR8]\] and in the IL23/Th17 signalling \[[@CR9]\]. *NOD2* mutations have been evidenced in granulomatous diseases, including Blau syndrome (BS), early onset sarcoidosis (EOS) and Crohn's disease (CD). NOD2 is a cytosolic protein involved in sensing microbial cell wall components and regulating inflammatory processes by activating NF-κB \[[@CR10]\]. A deficit in sensing bacteria in monocytes/macrophages might result in an exaggerated inflammatory response by the adaptive immune system. Thus *NOD2* mutations are considered to play a major role in the pathogenesis of granulomatous diseases \[[@CR11], [@CR12]\]. Variants may concern different NOD2 domains, NACHT domain for BS and EOS and LRR domain for CD \[[@CR11], [@CR13]\]. NACHT domain variants enhanced NOD2 activity, whereas LRR domain variants reduced NOD2.

Although scientific evidence was provided indicating that the NOD2 signalling pathway was involved in sarcoidosis pathogenesis, selection of patients with confirmed sarcoidosis from the Sarcoidosis Genetic Analysis study population \[[@CR14]\] and the ACCESS study \[[@CR15]\] with or without joint and skin involvement showed no evidence of *NOD2* mutation \[[@CR16]\]. Up to now, no study has evidenced any *NOD2* mutation in sarcoidosis with a late typical presentation. The role of the *NOD2* gene in sarcoidosis was associated with increase susceptibility for developing sarcoidosis \[[@CR17], [@CR18]\].

The SARCFAM project is a French national project on familial sarcoidosis which allowed the recruitment of more than 180 families with at least two first-degree affected members \[[@CR19]\]. Screening of nine sarcoidosis by WES has provided extensive and complex data which are included in a larger program of the SARCFAM project. Among this series, a subset of 10 families gathered more than 3 patients. One of them referred as "X" was of particular interest due to the identification of NOD2 variants, including the G908R mutation that has been described in Crohn's disease. Identification of the *NOD2* variant in the LRR domain (G908R in exon 8) was confirmed by Sanger sequencing.

In the present study, we report sarcoidosis presentation and history, NOD2 profile and NF-κB and cytokine production in blood monocytes in affected patients of the family X and to compare genetic and NF-κB and cytokine profiles with members of the family unaffected by sarcoidosis and safe controls.

Methods {#Sec2}
=======

Populations {#Sec3}
-----------

The study received institutional review board approval (CPP IRN number 00009118) according to French legislation. Written informed consent for all participants was obtained for genetic and biological investigations. Three groups were studied:

*Members of family X with confirmed sarcoidosis (n = 4)* (Table [1](#Tab1){ref-type="table"} and Fig. [1](#Fig1){ref-type="fig"}). Sarcoidosis diagnosis was made according to sarcoidosis statement \[[@CR20]\]. Three of them could be investigated (IB, IIA and IIB). In them, clinical presentation was typical, evidence of non caseating granulomas was obtained and there was no element in favour of any alternative granulomatous disease. None of them presented any element in favour of BS, EOS nor CD. In particular, there was no digestive tract history except for one patient with colic polyps who underwent twice colonoscopy without evidence of macroscopic or histologic arguments for CD.Table 1Clinical characteristics of family X membersFamily memberYear of birthSexAge at sarcoidosis diagnosisChest X ray stage^a^Extra-thoracic sarcoidosisSarcoidosis duration (years)Sarcoidosis treatmentIA1925M414no30not treatedIB1932F431skin34never treatedIIA1955M354PH28corticosteroidIIB1957M511spinal cord10corticosteroid/cyclphosphamid*M* male, *F* female; ^a^according to (17), *PH* pulmonary hypertension under specific vasodilatator treatmentFig. 1Pedigree of Family X with cases of pulmonary sarcoidosis. Circles represent females; squares represent males. Slashed symbol indicate deceased subjects. Individuals with confirmed sarcoidosis are indicated in black symbols. Relatives in grey symbols underwent a workup diagnosis (clinical examination, blood tests and chest X ray) that allowed to exclude sarcoidosis. The current age is indicated below each symbol. Numbers beside each symbol correspond to the individuals described in Table [1](#Tab1){ref-type="table"}. The directional arrow indicates the index case. His maternal grand-mother died in 1958. She was known to have recurrent asthma attacks. No medical file is available for this woman

*Members of family X unaffected by sarcoidosis (n = 2)* (Fig. [1](#Fig1){ref-type="fig"}). Two members of the family (IIC and IID), who were brother or sister of two patients, son or daughter of one patient and nephew or niece of the fourth patient, with no history of sarcoidosis were investigated in 2016. For both, clinical examination, chest X ray and blood biology including serum angiotensin converting enzyme were normal.

*Control volunteers (n = 4)*: Four normal volunteers, aged 69, 65, 48 and 53 with no history of sarcoidosis nor any known current disease served as normal controls.

Genetic testing {#Sec4}
---------------

Blood DNAs were obtained from three patients and tested for *NOD2 exon 8, IL17RA exon 11, KALRN exon 1 and EPHA2 exon 17* sequence variants. PCR reaction was performed as described in the Additional file [1](#MOESM1){ref-type="media"}.

Targeted exome sequencing {#Sec5}
-------------------------

Genomic DNA was captured using Agilent in-solution enrichment methodology (SureSelect Human Clinical Research Exome, Agilent) with the supplied biotinylated oligonucleotides probes library (Human Clinical Research Exome, Agilent), followed by paired-end 75 bases massively parallel sequencing on Illumina HiSEQ 4000. The DNA library was prepared as described in the Additional file [1](#MOESM1){ref-type="media"}.

Screening of SNP variants identified by WES {#Sec6}
-------------------------------------------

SNP variants identified in family X upon WES screening were analyzed for a putative functional effect on the protein by using the SIFT and Polyphenv2 softwares (see in the Additional file [1](#MOESM1){ref-type="media"}). The minor allele frequencies (MAF) were evaluated by the ExAC online database (see in the Additional file [1](#MOESM1){ref-type="media"}, Bioinformatics and Statistical and functional evaluation of variants in silico). A MAF less than 0.01 suggest a rare variant and not a common polymorphism.

Peripheral blood mononuclear cells isolation, culture and stimulations {#Sec7}
----------------------------------------------------------------------

Twenty mL of total blood sampled in EDTA tubes for routine hematology analysis were collected. Peripheral blood mononuclear cells (PBMCs) were isolated and differentiated in macrophages as described in the Additional file [1](#MOESM1){ref-type="media"}. Macrophages were then stimulated with either saline serum (Ctrl), or 10 μg/mL of N-Acetylmuramyl-L-alanyl-D-isoglutamine hydrate (MDP, muramyl dipeptide) (Sigma-Aldrich France), or 1 μg/ml Lipopolysaccharides from *Escherichia coli* 0111: B4 (LPS) (Sigma-Aldrich) for 1 h for the NF-κB activation study or 24 h for the transcriptional study.

NF-κB activation {#Sec8}
----------------

Activation of the different NF-κB family members (p50, p52, p65, c-Rel and RelB) was assayed using the TransAM® NF-κB Family kit (Active Motif, Belgium) according to the manufacturer's protocol.

RNA extraction and RT-QPCR {#Sec9}
--------------------------

RNA were prepared as described in Additional file [1](#MOESM1){ref-type="media"}. Quantitative PCRs were performed in presence of ABsolute QPCR Mix (Thermo Fisher Scientific) with primer sets specific to *TNF-A, IL-8, IL-6, NOD2* and *IL17RA* (see in the Additional file [1](#MOESM1){ref-type="media"}: Table S1).

Results {#Sec10}
=======

Sarcoidosis presentation, outcome and treatment {#Sec11}
-----------------------------------------------

Sarcoidosis presentation, outcome and treatment are shown in Table [1](#Tab1){ref-type="table"}. Sarcoidosis was diagnosed in 35, 41, 43 and 51-year-old patients. Typical bilateral hilar lymphadenopathy was evidenced on thorax imaging in all four cases with lung infiltration in two cases. Bilateral upper lobes fibrosis was seen in two cases, associated with pulmonary hypertension in only one case. Other manifestations were respectively skin lesions for IB and spinal cord localization for IIB. In three cases (IB, IIA, IIB), there was a prolonged course (respectively 35, 27 and 9 years) with no healed case till now. Patient IB with a well-tolerated chronic sarcoidosis has upper lobes pulmonary fibrosis with calcification of hilar and mediastinal lymph nodes. She received no systemic therapy for sarcoidosis, except treatment for recurrent infectious exacerbations. The exact duration of the disease course is unknown. For IIA, a corticosteroid treatment was given after 20 years due to lung progression and occurrence of lung fibrosis. There was a good response with glucocorticoids which could be tapered until 7 mg/d with no evidence of residual activity on recent investigations. Eventually, for IIB, because of spinal cord involvement, a treatment associating high doses of corticosteroids and cyclophosphamide was given with a favourable response. Now, treatment consists in low doses of prednisone without relapse.

NOD2 investigation {#Sec12}
------------------

The *NOD2* variant (SNP - Ggc/Cgc -- rs2066845 -- position chr.16.50756540 -- transcript NM_022162) identified in this family is a missense mutation previously described in the context of Crohn's disease. It consists of a G908R substitution located in exon 8. The minor allele frequency as suggested by the ExAC database is 0,009917 (<http://exac.broadinstitute.org/>). In family X, this variant was found in the three patients with sarcoidosis and one among two offsprings free of the disease. No control had NOD2 mutation. In addition, selective extraction of rare variants from WES data allowed us to identify three other single nucleotide variants in the three patients with sarcoidosis. These SNPs target the coding regions of the *IL17RA*, *KALRN* and *EPHA2* genes, causing either missense (*IL17RA, EPHA2*) or nonsense (*KALRN*) variants. Data on the various SNPs are summarized in Table [2](#Tab2){ref-type="table"}. In the series of 9 families screened by WES and including family X, a total of 7 deleterious and /or rare variants was observed in the three genes, either *EPHA2* (3 variants in 3 families), *KALRN* (2 variants in 2 families) and *IL17RA* (2 variants in 2 families) (Table [3](#Tab3){ref-type="table"}). The rs139787163 variant of *EPHA2* (p.Ala951Thr) was observed two times despite a very low MAF value (ExAC: 0.000346).Table 2Description of heterozygous variants identified by whole-exome-sequencing in the family XGene variant*NOD2 2722G \> C*\
*exon 8*\
NM_022162*IL17RA 958 T \> C*\
*exon 11*\
NM_014339.6*KALRN 28C \> T*\
*exon 1*\
NM_007064.3*EPHA2 2875G \> A*\
*exon 17*\
NM_004431.3Chr.162231Position50,756,54017,586,757124,303,69616,451,766QUAL25213844457810,401Deph278370528618rs ID numberrs2066845rs140221307rs56407180rs139787163Single nucleotide variantmissensemissensenonsensemissensePolyPhen2 prediction0.986^a^0.972^a^STOP^a^0.828^a^SIFT0.010^a^STOP^a^0.05^a^EXaC global MAF0.0099170.0018010.0023820.00346ProteinNOD2 G908RIL17RA W320R--EPHA2 A959TPrior associations with diseaseCrohn's disease, Psoriatic arthritis, Blau syndromeFamilial Candidiasis--Age-related cortical cataractPatient IBHetHetHetHetPatient IIAHetHetHetHetPatient IIBHetHetHetHetPatient IICHetAAAPatient IIDAAAA*Het* heterozygous, *A* minor allele (C) absent, *Chr* chromosome, *SNP* single nucleotide polymorphism; Depth represents the number of reads identifying the SNP variant. QUAL., a quality parameter measuring the probability p that the observation of the variant is due to chance (for ex: QUAL = n, *p* = 1/n). It includes the DEPTH parameter and the coverage of the genomic sequence. The in silico functional evaluation of SNP variants was performed by using bioinformatics softwares SIFT, PolyPhen-2. The value indicating a putative pathogenic effect are near of 0 for SIFT and near of 1 for Polyphenv2, as indicated by the ^a^. The minor allele frequency of SNP variants were evaluated by using the ExAC online database (<http://exac.broadinstitute.org/>). A global MAF including all ethnic origins lower than 0.01 suggest a rare variation and not a common polymorphismTable 3Variants identified in other SARCFAM familiesGENErsExonCodonTYPEEFFECTSIFTPOLYPHENAccessionNumber of familyMAF (ExAC)NUCLEOTIDEChRPOSITIONDEPTH miniEPHA2rs1397871633959missenseAla959Thr0,050,828NM_004431.3Family X0.000346Gcc/Acc116,451,76648EPHA2rs1507903603165missenseVal165met00,062NM_00443110.001535Gtg/Atg116,475,203157EPHA2rs13978716317959missenseAla959Thr0,050,828NM_00443110.000346Gcc/Acc116,451,76648KALRNrs56407180110nonsenseArg10terSTOPGAINNM_007064.3Family X0.002382c.28C \> T3124,303,696528KALRNrs35298864381930missenseArg1930Met00,891NM_00102466010.007276aGg/aTg3124,369,782178IL17RArs14022130711320missenseTrp320Arg00,972NM_014339.6Family X0.001801c.958 T \> C2217,586,757370IL17RArs4132364513691missenseAla691Thr0,350,926NM_014339.610.3023c.2071G \> A2217,590,180160Additional informations on IL17RIL17RBrs22323469278missensePhe278Leu0,650NM_018725.3Family X0.01915c.832 T \> C353,892,830141IL17RCnd6ndsplice donorframeshiftsplicingdefect1ndc.790 + 1G \> T39,962,287155

NFκB activation is reduced in sarcoidosis patients with NOD2 G208R mutation {#Sec13}
---------------------------------------------------------------------------

Activation of NOD2 promotes its binding to RIP2 kinase, triggering the complex activation and initiating the activation of multiple complexes, including MAP kinases and IκB kinases \[[@CR21]\]. This activation allowed the release of active NF-κB/Rel complexes that translocate to the nucleus where they induce target gene expression involved in innate and adaptive immunity, inflammation, stress responses, B-cell development, and lymphoid organogenesis. In the present study, activation of different NF-κB family members (p50, p52, p65, c-Rel and RelB) was assayed in monocytes and macrophages in basal condition or in response to either MDP (specific NOD2 activator) or LPS from control subjects or family members. NF-κB p50 and p65 activations were increased in response to MDP and LPS stimulation in both control subjects and family patients, except the patient IB whose macrophages poorly responded to both treatments (Fig. [2a](#Fig2){ref-type="fig"}, [b](#Fig2){ref-type="fig"}). Similarly, NF-κB p52 activation was less in macrophages from patient IB (Fig. [2c](#Fig2){ref-type="fig"}). No major differences were observed in NF-κB cRel and RelB activation in macrophages from control subjects or family members in stimulated by MDP or LPS (Fig. [2d](#Fig2){ref-type="fig"}, [e](#Fig2){ref-type="fig"}).Fig. 2NF-κB activation is decreased in untreated NOD2 G208R sarcoidosis patient. NFκB activation (p50 (**a**), p65 (**b**), p52 (**c**), RelB (**d**), cRel (**e**)) (measured as OD450 nm) was assessed by TransAM NFκB kit (Active Motif) in control (C) and family X (F) monocytes (Mono) or monocytes derived macrophages (MФ) in basal condition (Ctrl) or treated with MDP or LPS for 1 h

To determine whether reduced NF-κB activation in untreated NOD2 G208R sarcoidosis patient (IB) decreases inflammatory cytokines expression, mRNA levels for *IL-8, TNF-A, IL-6* genes were assessed by quantitative RT-PCR (qRT-PCR) in monocytes and macrophages in basal condition or in response to either MDP or LPS from control subjects or family members. Strikingly, both *IL-8* and *TNF-A* mRNAs were expressed at high levels in macrophages from patient IB in basal and stimulated conditions compared to other family members and control subjects (Fig. [3a](#Fig3){ref-type="fig"}, [b](#Fig3){ref-type="fig"}). By contrast, *IL-6* mRNA levels were similar in both groups in each culture conditions (Fig. [3c](#Fig3){ref-type="fig"}). In addition, NOD2 mRNA levels were increased in patient IB in basal condition and in response to MDP (Fig. [3d](#Fig3){ref-type="fig"}). By contrast, IL17RA were similar in both groups in each culture conditions (Fig. [3e](#Fig3){ref-type="fig"}).Fig. 3Up-regulation of *IL-8* and *TNF-A* expression in untreated NOD2 G208R sarcoidosis patient. *IL-8* (**a**), *TNF-A* (**b**), *IL-6*  (**c**),*NOD2* (**d**) and *IL17RA* (**e**) mRNA levels were assessed by RT-qPCR in control (C) and family X (F) monocytes (Mono) or monocytes derived macrophages (MФ) in basal condition (Ctrl) or treated with MDP or LPS for 24 h

Discussion {#Sec14}
==========

To our knowledge, this is the first time that the *NOD2 2722G \> C* (rs2066845) variant substituting a Glycine to Arginine at codon 908 in exon 8 in the leucine rich repeat (LRR) domain of the NOD2 protein is reported in a case of familial sarcoidosis with late and typical presentation of the disease. This variant was observed in an unaffected relative, suggesting that other genetic and/or epigenetic factors may contribute to the occurrence of the disease. Indeed, WES analysis discriminated affected versus unaffected individuals by three putative pathogenic SNP variants in the *IL17RA*, *KALRN* and *EPHA2* genes.

NOD2 is essential in regulating both inflammatory and immunologic homeostasis. *In silico* pathogenic evaluation (p) with the SIFT (*p* = 0.01) and POLYPHENv2 (PSIC score difference = 2.407) suggest a strong disturbing effect on the primary amino acid sequence raising the question of a significant impact in sarcoidosis pathogenesis. The role of the G908R mutation of the *NOD2* gene in sarcoidosis is controversial either with increase susceptibility for developing sarcoidosis \[[@CR17], [@CR18]\] or a minor role of the *2722G \> C* variant in the pathogenesis of sarcoidosis \[[@CR22]--[@CR24]\]. In the present case of familial sarcoidosis, 3 out of 4 patients with the variant *2722G \> C* developed sarcoidosis, while the other unaffected offspring did not carry the variant. Observation of a family member with NOD2 variant but no sarcoidosis is similar to the numerous individuals free of any disease, particularly of CD despite carrying the same variant, indicating that gene/environmental interactions and possibly gene/gene interactions (epistasis) are also essential \[[@CR25]\]. Such association of sarcoidosis with the *NOD2 2722G \> C* variant is certainly a very rare finding. It was not observed in Bello's paper focused on adult patients with sarcoidosis involving eyes, skin and joints as in EOS and BS \[[@CR16]\]. In our nine other families with at least 3 members affected, none was associated to any *NOD2* variant. Among our family collection, families with 3 or more affected members (*n* = 10) represent probably a small subset among sarcoidosis families with probably specific genetic predisposal or shared environmental factors.

It is of particular interest to observe the *NOD2 2722G \> C* variant associated with a very typical presentation of sarcoidosis, all patients showing bilateral hilar lymphadenopathy and lymphatic distribution of lung micronodules distinct from EOS when lung involvement was present \[[@CR26]\]. By contrast evidence of lung infiltration is very rare in EOS with a very different radiologic pattern and no lymphadenopathy \[[@CR11]\]. Another question is the impact of NOD2 variant on the outcome which was characterized by a very long course in all patients, a condition usual in CD and perhaps associated to persistent abnormalities of microbiota induced by the variant. Indeed, deletion of *Nod2* in mice reduced bacterial activity in the gut, promoting an increased susceptibility to colonization by both the commensal microbiota and pathogenic bacteria, thus triggering intestinal inflammation \[[@CR27]\]. In addition, *Nod2* deletion impairs autophagy in macrophages allowing intracellular survival of bacteria delaying bacterial clearance \[[@CR28]\]. In our family, any confusion with CD either as main diagnosis or as comorbidity was ruled out by the absence of suggestive history of digestive tract disease particularly in one patient who had two colonoscopic examinations.

Both gain of function NOD2 mutant alleles like in BS and EOS and loss of function NOD2 mutant alleles like in most common CD and probably in our family with sarcoidosis might induce autoinflammatory disorders \[[@CR29], [@CR30]\]. During sarcoidosis, NF-κB is activated in site of organ involved \[[@CR31]--[@CR33]\]. In BS and EOS, gain of function NOD2 variants are associated with NF-κB activation. By contrast, we observed NFκB downregulation in our untreated patient as in CD patients with the *NOD2 2722G \> C* variant. These data are supported by *in vitro* experiments showing that NFκB activity is reduced at baseline and in response to MDP in HEK293T cells expressing the *NOD2 2722G \> C* variant \[[@CR34]--[@CR36]\]. Interestingly, NF-κB activity was upregulated in response to MDP in family X treated patients as well as the unaffected carrier of the variant, similarly to normal controls suggesting that treatments efficient against sarcoidosis activity may restore NF-κB activity altered by the presence of the *NOD2 2722G \> C* variant. Indeed, patients treated by glucocorticoids responded well to the treatment, indicating that they were not refractory to corticoids \[[@CR37]\] by comparison to Crohn disease patients \[[@CR38]\]. Although increased NF-κB activity in patients with corticoids is obviously in conflict with what could be expected with anti-inflammatory drugs, previous studies showed that glucocorticoids could potentially contribute to pro-inflammatory activation by inducing the expression of the Macrophage migration inhibitory factor \[[@CR39]\]. By contrast, in response to LPS stimulation, NF-κB activity was maintained in the untreated patient IB to similar levels observed in family X treated patients and normal controls, indicating that stimulation of NF-κB through NOD2- independent pathways remains possible. NF-κB is an important transcription factor for genes encoding cytokines like *IL-8* and *TNF-A*, this last one being a corner stone in sarcoidosis pathogenesis. In patient IB, despite a decrease in NF-κB activity, *IL-8* and *TNF-A* mRNA levels were increased at baseline and in stimulated conditions, indicating a chronic pro-inflammatory status in macrophages. As in Crohn disease patients with the *NOD2 2722G \> C* variant, patient IB led to an apparent paradox: reduced NF-κB transactivating activity associated with more inflammation. Recently Strober et al\... showed that in mice, activation of NF-κB in response to ligands to toll-like receptor 2 (TLR-2) is down-regulated by NOD2 \[[@CR40]\]. In the absence of an efficient form of NOD2 the TLR signaling pathway is maintained, leading to increased production of inflammatory cytokines and the development of pathogenesis. Other data suggest that virulence and pathogens factors may trigger the NOD1/NOD2 signaling pathway indirectly by activating Rac1 \[[@CR41]\]. Rac1 has been shown to upregulate NF-κB activity in a PAK1 (p21-activated kinase) dependent manner by stimulating the nuclear translocation of p65 subunit of NF-κB \[[@CR42]\]. In addition, Hedl et al showed that acute stimulation of NOD2 triggered in human macrophages the secretion of anti-inflammatory cytokines, including IL-10 and IL1ra \[[@CR43]\]. Thus, we could hypothesize that in *NOD2 2722G \> C* patients, an imbalance occurs in favour of a pro-inflammatory phenotype.

One of the major issue was to find any genetic data which might discriminate family X members expressing clinically the disease from the others. Remarkably, in addition to *NOD2 2722G \> C*, three single nucleotide variants for the *IL17RA*, *KALRN* and *EPHA2* genes were found in the family X patients with sarcoidosis. By comparison, as shown in Table [3](#Tab3){ref-type="table"}, screening of the nine families by WES analysis showed the presence of single deleterious variants in a total of 7 families out of 9, one of them (*EPHA2* -- rs139787163) being common in two distinct families despite a very low minor allele frequency (MAF = 0.000346).

The *IL17RA 958 T \> C* variant modifies the amino acid sequence in the extracellular domain of the IL17RA, possibly altering its function. IL17RA (interleukin 17A receptor) is capable to form a heterodimer complex to bind both interleukin 17A and IL-25. IL17RA plays a pathogenic role in many inflammatory and autoimmune diseases, including rheumatoid arthritis, psoriasis, *Candida albicans* infection and Crohn disease \[[@CR44]--[@CR46]\]. Activation of IL17RA leads to induction of expression of inflammatory cytokines such as CXCL1, CXCL8/IL8 and IL6 through the trans-activation of NF-κB, AP-1 and C/EBPβ. Involvement of IL17 signalling was shown in sarcoidosis \[[@CR47]\]. Notably, IL-17--producing T cells are increased in peripheral blood and lungs of subjects with sarcoidosis compared with controls \[[@CR48]\]. In addition, IL-17A plays a major role in granuloma formation in response to mycobacterial infections in mice \[[@CR49], [@CR50]\]. Likewise Th17 cells have been implicated in the development of Crohn's disease \[[@CR51]\]. Notably, McGovern et al\... showed that IL17RA genetic variants increased susceptibility to inflammatory bowel disease pathogenesis and demonstrated the cumulative risk of IL17RA variants with genes of the IL23/IL17 pathway in the development of CD \[[@CR46]\]. Interestingly, Kurdy et al demonstrated that IL17 is directly regulated at the transcriptional level by a complex including Rac1, Tiam1 and RORχt (RAR-related orphan receptor gamma), the master transcription and differentiation factor of Th17 cells \[[@CR52]\].

The *EPHA2 2875G \> A* variant is located within the conserved cytoplasmic domain of the receptor. This variant was associated with age-related cortical cataract \[[@CR53]--[@CR56]\]. Erythropoietin-producing hepatoma (Eph) receptors are a family of receptor tyrosine kinases that can bind ephrin ligands. EphA receptors are expressed on CD4^+^ and CD8^+^ T cells, dendritic cells (DCs), and Langherans cells \[[@CR57], [@CR58]\] and are involved in T cell function \[[@CR59]\]. Eph receptors are involved in axon guidance, vascularization, tissue assembly, and cell adhesion and migration \[[@CR60]--[@CR63]\]. Khounlothm et al\... showed that EphA receptors play a role in the pathogenesis of *M. tuberculosis* infection by reducing the migration of T cells and DCs to the site of infection, producing an environment that favours bacterial persistence \[[@CR64]\]. Activated EPHA2 interacts with Rho family GEF in endosomes and play a role in ephrin-dependant Rac1 activation \[[@CR65]\]. Interestingly, variants for EPH receptor family members have been associated with inflammatory bowel diseases. Hafner et al showed an increased expression of Eph-B2 that increased epithelial cell mobility in the intestinal epithelium of Morbus Crohn patients \[[@CR66]\].

The KALRN 28C \> T variant is a non-sense variant targeting Kalirin, a multidomain guanine nucleotide exchange factor (GEF) for small GTP-binding proteins of the Rho family. Multiple kalirin isoforms containing different combinations of functional domains are predominantly expressed in brain, except KALRN 9 that is more widely expressed \[[@CR67]\]. Kalirin is known to be involved in active remodeling of synapses and dendritic maturation in early development \[[@CR68]\]. Kalirin was also shown to play a neuroprotective role during inflammation of the central nervous system by inhibiting iNOS activity \[[@CR69]\]. In smooth muscle cells, Kalirin interacts with Rac1, promoting SMC migration and proliferation \[[@CR70]\]. Thus, it appears that both EPHA2 and KALRN are implicated in dendritic cell maturation and migration. Dendritic cells have been implicated in sarcoidosis \[[@CR71]\]. Mathew et al. showed that myeloids DCs function was reduced in sarcoidosis patients, possibly contributing to susceptibility and persistence of the chronic inflammation \[[@CR72]\]. Interestingly in family X, member IIC who carries the *NOD2 2722G \> C* variant only*,* did not develop sarcoidosis. These data suggest that the *NOD2 2722G \> C* variant was not sufficient to trigger pulmonary sarcoidosis by itself and it is the presence of other variants (*IL17RA 958 T \> C, EPHA2 2875G \> A* and *KALRN 28C \> T)* that contribute to the pathology in patients with pulmonary sarcoidosis of family X, perhaps by enhancing the development and chronicity of pulmonary sarcoidosis in family X.

Taken together, our data suggest a functional and pathogenic link between EPHA2, KALRN and IL17RA in the occurrence of the disease of family X sarcoidosis patients, acting in addition to the NOD2 functional defect.

Conclusions {#Sec15}
===========

For the first time in the literature, we described the presence of the *NOD2 2722G \> C* variant in a case of familial sarcoidosis. Our finding further establishes that the *NOD2 2722G \> C* variant in combination with variants for *IL17RA*, *EPHA2* and *KALRN* genes could play a significant role in the development of sarcoidosis. Future functional studies are required to reveal the causal regulatory variation of the various loci and the immunogenetic basis related to sarcoidosis.
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